PHOENIX, Jan. 4, 2012 /PRNewswire/ -- Kedem Pharmaceuticals Inc. (OTCBB: KDMP), a specialty pharmaceutical company with focus on sublingual drug delivery is pleased to announce that it has signed a contract with a GMP pharmaceutical FDA compliant formulation development company, Corealis Pharma, Inc. for the production of the phase I clinical supplies of KDM-1102, the Company's second lead therapeutic drug. The KDM-1102 drug is a new sublingual formulation of propanolol. The formulation development of the KDM-1102 drug is now completed and can be produce in large volume.
"We are pleased with the progress we have been making in our development program on KDM-1102, our Second lead therapeutic drug for cardiovascular and anxiety attacks," said Dr. Hassan Salari, Kedem Pharmaceuticals, President & CEO.
About Sublingual Technology
The Company's sublingual formulation is designed to enhance drugs to be delivered to the body without the need for injection. This design enables the vast majority of pharmaceutical drugs to be rapidly absorbed through the mucosal membrane (tissues of the mouth) quickly and efficiently. This technology works well for drugs that need faster results and have major side effects associated with gastrointestinal and/or liver break down. It is scientifically accepted that sublingual drug delivery route is the fastest and most efficient way of drug delivery after direct injection. The technology may apply to over 40 major drugs which all can benefit from this route.
About Kedem Pharmaceuticals Inc. (KDMP.ob) is a specialty pharmaceutical company with expertise in drug delivery and formulation. The Company's lead therapeutic product is a male sexual enhancement drug that is delivered via sublingual route and is called X-Excite. The Company has several other drugs under development for fast and convenient delivery. These include drugs for anxiety attack, osteoporosis, sleeping disorders, pain killers, migraine, anti-allergy medications, cardiovascular diseases, lung medications, and addiction replacement therapies.
About Corealis Pharma Inc. is a private Montreal based contractual formulation development and clinical supply manufacturing company of pharmaceutical oral solid dosage forms for United-States, European, and Canadian trials (www.corealispharma.com).
This press release includes forward-looking statements that involve a number of risks and uncertainties, including the success of the products in commercializing and developing. Additionally this press release include statement within the meaning of the Private Securities Litigation Reform Act of 1995, that are subject to high risks, uncertainties and other factors, including that the Regulatory Agencies may not agree to the claims made in the Company documents related to our products, and product development. There are risks that due to unforeseen reasons, matters could cause the actual results to differ materially from those referred in our fillings. Risks involved patent infringement, trademark and other commercially related actions that hinder the product development and marketing. Additional risks involve the ability of the Company to raise capital to fund its operations and the capital requirements for the development and marketing of its products. Investors are encouraged to review the risk factors listed or described from time to time in the Company's filings (10K) with the Securities and Exchange Commission, as well as to obtain independent third party opinions before investing in the Company's securities.
For further information, contact:
Kedem Investor Relations 1 866 465-6551
Premier Media Services 1 480 649 8224
SOURCE Kedem Pharmaceuticals Inc.